Abstract
Radiation has been a well-established modality in cancer treatment for several decades. Significant improvements have been achieved in radiotherapy over the years due to technological advances and development of facilities for delivery of charged particles such as protons. Nonetheless, the potential for tumor control with radiotherapy must always be carefully balanced with the risk for normal tissue damage. In addition, tumor cells outside the immediate field of radiation exposure or that have metastasized to distant sites are not destroyed. Gene therapy offers many exciting possibilities by which the overall efficacy of radiotherapy may be improved, while minimizing unwanted side effects. This review highlights several of the most promising gene transfer approaches that are currently being evaluated in combination with radiation in the treatment of cancer. Results from studies utilizing genes encoding molecules that function in apoptosis, radiosensitization, immune up-regulation, angiogenesis, DNA repair, normal tissue protection from radiation damage, and tumor targeting are discussed. The evidence indicates that many of these innovative gene-based strategies have great potential to augment radiotherapy, as well as other established forms of cancer treatment, in the near future.
Keywords: ionizing radiation, protons, radiosensitization, radiation-inducible promoters, targeted gene therapy, suicide genes, immunogenes
Current Gene Therapy
Title: Combining Gene Therapy and Radiation Against Cancer
Volume: 4 Issue: 3
Author(s): Daila S. Gridley and James M. Slater
Affiliation:
Keywords: ionizing radiation, protons, radiosensitization, radiation-inducible promoters, targeted gene therapy, suicide genes, immunogenes
Abstract: Radiation has been a well-established modality in cancer treatment for several decades. Significant improvements have been achieved in radiotherapy over the years due to technological advances and development of facilities for delivery of charged particles such as protons. Nonetheless, the potential for tumor control with radiotherapy must always be carefully balanced with the risk for normal tissue damage. In addition, tumor cells outside the immediate field of radiation exposure or that have metastasized to distant sites are not destroyed. Gene therapy offers many exciting possibilities by which the overall efficacy of radiotherapy may be improved, while minimizing unwanted side effects. This review highlights several of the most promising gene transfer approaches that are currently being evaluated in combination with radiation in the treatment of cancer. Results from studies utilizing genes encoding molecules that function in apoptosis, radiosensitization, immune up-regulation, angiogenesis, DNA repair, normal tissue protection from radiation damage, and tumor targeting are discussed. The evidence indicates that many of these innovative gene-based strategies have great potential to augment radiotherapy, as well as other established forms of cancer treatment, in the near future.
Export Options
About this article
Cite this article as:
Gridley S. Daila and Slater M. James, Combining Gene Therapy and Radiation Against Cancer, Current Gene Therapy 2004; 4 (3) . https://dx.doi.org/10.2174/1566523043346318
DOI https://dx.doi.org/10.2174/1566523043346318 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia
Current Drug Therapy Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Luminescent Quantum Dots: A Very Attractive and Promising Tool in Biomedicine
Current Medicinal Chemistry The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research